Appia Bio
ClosedLos Angeles, United States · Founded 2020 · $52.0M raised
- Headquarters
- Los Angeles, California
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- appiabio.com
- Total Funding
- $52.0M
- Last Round
- $52.0M Series AMay 2021
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Appia Bio was a California-based cell therapy company preparing to file an investigational new drug application for off-the-shelf therapies that involve reprogramming stem cells into a rare type of tumor-targeting immune cell called invariant natural killer T (iNKT) cells. Founding CEO JeenJoo "JJ" Kang wrote that the team "steadfastly made scientific progress and got to the cusp of filing our IND for clinical testing," but the company ran out of funds to advance into human trials and closed up shop.
Summary
Appia Bio is a Biotech company based in Los Angeles, United States, founded in 2020. It has raised $52.0M in total across 1 round, most recently a $52.0M Series A round in May 2021. Investors include 8VC and Two Sigma Ventures.
Funding History
May 2021
Investors
Similar Companies
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/appia-bio"><img src="https://indexed.vc/api/badge/company/appia-bio" alt="Appia Bio on Indexed.vc" width="260" height="76" /></a>